However, pharmacological inhibition of STAT3 did not completely abrogate GRIM-19 loss-driven tumorigenesis, suggesting that the full capacity of GRIM-19 loss to tumor growth may extend beyond its ability to activate STAT3. The gene discussed is STAT3; the disease is neoplasm.